Back

Multifaceted roles of SAMHD1 in cancer

McLaughlin, K.-M.; Cinatl, J.; Wass, M. N.; Michaelis, M.

2021-07-05 cancer biology
10.1101/2021.07.03.451003 bioRxiv
Show abstract

SAMHD1 is discussed as a tumour suppressor protein, but its potential role in cancer has only been investigated in very few cancer types. Here, we performed a systematic analysis of the TCGA (adult cancer) and TARGET (paediatric cancer) databases, the results of which did not suggest that SAMHD1 should be regarded as a bona fide tumour suppressor. SAMHD1 mutations that interfere with SAMHD1 function were not associated with poor outcome, which would be expected for a tumour suppressor. High SAMHD1 tumour levels were associated with increased survival in some cancer entities and reduced survival in others. Moreover, the data suggested differences in the role of SAMHD1 between males and females and between different races. Often, there was no significant relationship between SAMHD1 levels and cancer outcome. Taken together, our results indicate that SAMHD1 may exert pro-or anti-tumourigenic effects and that SAMHD1 is involved in the oncogenic process in a minority of cancer cases. These findings seem to be in disaccord with a perception and narrative forming in the field suggesting that SAMHD1 is a tumour suppressor. A systematic literature review confirmed that most of the available scientific articles focus on a potential role of SAMHD1 as a tumour suppressor. The reasons for this remain unclear but may include confirmation bias and publication bias. Our findings emphasise that hypotheses, perceptions, and assumptions need to be continuously challenged by using all available data and evidence.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Molecular Oncology
55 papers in training set
Top 0.1%
14.9%
2
Genome Medicine
183 papers in training set
Top 0.4%
6.7%
3
eLife
5828 papers in training set
Top 19%
6.2%
4
Cancers
213 papers in training set
Top 1%
5.4%
5
Cancer Letters
35 papers in training set
Top 0.1%
4.8%
6
Scientific Reports
3612 papers in training set
Top 27%
4.0%
7
International Journal of Cancer
49 papers in training set
Top 0.2%
4.0%
8
Acta Neuropathologica Communications
89 papers in training set
Top 0.5%
4.0%
9
PLOS ONE
5266 papers in training set
Top 38%
3.2%
50% of probability mass above
10
Clinical Epigenetics
60 papers in training set
Top 0.2%
3.1%
11
BMC Cancer
67 papers in training set
Top 0.8%
2.8%
12
NAR Cancer
37 papers in training set
Top 0.2%
2.4%
13
Oncogene
85 papers in training set
Top 1%
1.7%
14
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.4%
1.4%
15
International Journal of Molecular Sciences
494 papers in training set
Top 9%
1.4%
16
BMC Biology
265 papers in training set
Top 3%
1.3%
17
Cellular and Molecular Life Sciences
96 papers in training set
Top 1%
1.1%
18
Genome Biology
637 papers in training set
Top 7%
1.1%
19
British Journal of Cancer
49 papers in training set
Top 1%
1.1%
20
Communications Biology
993 papers in training set
Top 22%
1.1%
21
Frontiers in Oncology
103 papers in training set
Top 3%
1.1%
22
Life Science Alliance
285 papers in training set
Top 6%
1.1%
23
Nature Communications
5641 papers in training set
Top 57%
0.8%
24
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.8%
25
Cancer Research Communications
51 papers in training set
Top 2%
0.8%
26
iScience
1154 papers in training set
Top 35%
0.8%
27
Cell Reports
1498 papers in training set
Top 27%
0.8%
28
Frontiers in Bioinformatics
49 papers in training set
Top 1%
0.8%
29
PLOS Genetics
862 papers in training set
Top 12%
0.8%
30
Cancer Research
130 papers in training set
Top 3%
0.8%